Cubist Systematic Strategies’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Cubist Systematic Strategies’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,102	Closed	-$10.9K	–	4304
2024 Q1	$10.9K	Sell	4,102 -8,425	-67%	-$20.9K	﹤0.01%	3507
2023 Q4	$29.7K	Sell	12,527 -31,189	-71%	-$55.2K	﹤0.01%	3320
2023 Q3	$61.2K	Sell	43,716 -67,196	-61%	-$161K	﹤0.01%	3008
2023 Q2	$336K	Buy	+110,912	New	+$428K	﹤0.01%	2581
2023 Q1	–	Sell	-18,386	Closed	-$112K	–	4601
2022 Q4	$112K	Buy	18,386 +8,071	+78%	+$65.7K	﹤0.01%	3775
2022 Q3	$123K	Buy	+10,315	New	+$135K	﹤0.01%	3950
2021 Q4	–	Sell	-7,361	Closed	-$169K	–	3696
2021 Q3	$169K	Buy	+7,361	New	+$160K	﹤0.01%	2634

Cubist Systematic Strategies's KNTE Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 4,102 shares — an estimated $10.9K sold.

Cubist Systematic Strategies first reported a position in KNTE in Q3 2021 and held it in 7 quarters. The position peaked at $336K in Q2 2023. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

Cubist Systematic Strategies reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 4,102 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $10.9K.
Cubist Systematic Strategies first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Cubist Systematic Strategies's Kinnate Biopharma Inc. Common Stock position peaked at $336K in Q2 2023.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.